Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSD NASDAQ:IFRX NASDAQ:IMMP NASDAQ:TRIL NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$3.78+2.2%$4.93$3.32▼$19.80$19.81M2.05111,046 shs7,559 shsIFRXInflaRx$1.19-4.4%$1.26$0.71▼$2.82$79.55M1.4472,068 shs697,558 shsIMMPPrima BioMed$2.06-1.7%$1.76$1.32▼$2.71$303.80M1.87153,428 shs84,790 shsTRILDefiance Trillion Dollar Club Index ETF$19.74-0.6%$18.12$5.80▼$20.96$2.07B2.081.87 million shs1,557 shsXERSXeris Biopharma$9.26+1.3%$7.86$2.82▼$9.41$1.49B0.392.48 million shs1.67 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical-9.98%-15.14%+3.64%-39.84%-77.98%IFRXInflaRx-0.80%-15.07%+8.77%+43.52%-17.88%IMMPPrima BioMed-0.94%+3.45%+24.26%+23.53%+2.94%TRILDefiance Trillion Dollar Club Index ETF+0.53%-2.35%+7.68%+7.68%+7.68%XERSXeris Biopharma-1.40%+11.60%+22.36%+78.86%+200.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$3.78+2.2%$4.93$3.32▼$19.80$19.81M2.05111,046 shs7,559 shsIFRXInflaRx$1.19-4.4%$1.26$0.71▼$2.82$79.55M1.4472,068 shs697,558 shsIMMPPrima BioMed$2.06-1.7%$1.76$1.32▼$2.71$303.80M1.87153,428 shs84,790 shsTRILDefiance Trillion Dollar Club Index ETF$19.74-0.6%$18.12$5.80▼$20.96$2.07B2.081.87 million shs1,557 shsXERSXeris Biopharma$9.26+1.3%$7.86$2.82▼$9.41$1.49B0.392.48 million shs1.67 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical-9.98%-15.14%+3.64%-39.84%-77.98%IFRXInflaRx-0.80%-15.07%+8.77%+43.52%-17.88%IMMPPrima BioMed-0.94%+3.45%+24.26%+23.53%+2.94%TRILDefiance Trillion Dollar Club Index ETF+0.53%-2.35%+7.68%+7.68%+7.68%XERSXeris Biopharma-1.40%+11.60%+22.36%+78.86%+200.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 2.17Hold$63.001,566.67% UpsideIFRXInflaRx 2.67Moderate Buy$6.20423.21% UpsideIMMPPrima BioMed 2.00Hold$7.00239.15% UpsideTRILDefiance Trillion Dollar Club Index ETF 0.00N/AN/AN/AXERSXeris Biopharma 2.75Moderate Buy$7.08-23.46% DownsideCurrent Analyst Ratings BreakdownLatest CLSD, IFRX, XERS, IMMP, and TRIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025IFRXInflaRxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/13/2025XERSXeris BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025IMMPPrima BioMedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025XERSXeris BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IFRXInflaRxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMMPPrima BioMedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XERSXeris BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/2/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.008/19/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.008/12/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.007/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$75.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$1.66M11.93N/AN/A($7.68) per share-0.49IFRXInflaRx$180K441.94N/AN/A$1.13 per share1.05IMMPPrima BioMed$6.69M45.41N/AN/A$0.63 per share3.28TRILDefiance Trillion Dollar Club Index ETF$150K13,817.34N/AN/A$2.56 per share7.71XERSXeris Biopharma$203.07M7.36N/AN/A($0.20) per share-46.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$5.55N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)IFRXInflaRx-$49.85M-$0.80N/AN/AN/AN/A-71.76%-57.68%11/14/2025 (Estimated)IMMPPrima BioMed-$39.78MN/A0.00N/AN/AN/AN/AN/AN/ATRILDefiance Trillion Dollar Club Index ETF-$59.35M$0.6231.84N/AN/AN/A-23.31%-18.66%N/AXERSXeris Biopharma-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)Latest CLSD, IFRX, XERS, IMMP, and TRIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025IFRXInflaRx-$0.16N/AN/AN/AN/AN/A11/14/2025Q3 2025XERSXeris Biopharma$0.01N/AN/AN/AN/AN/A11/11/2025Q3 2025CLSDClearside Biomedical-$0.67N/AN/AN/A$0.09 millionN/A8/8/2025Q2 2025CLSDClearside Biomedical-$1.80-$0.90+$0.90-$0.06$0.50 million$0.49 million8/7/2025Q2 2025IFRXInflaRx-$0.24-$0.24N/A-$0.24$0.02 million$0.05 million8/7/2025Q2 2025XERSXeris Biopharma-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/ATRILDefiance Trillion Dollar Club Index ETFN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.873.87IFRXInflaRxN/A4.103.78IMMPPrima BioMedN/A11.69N/ATRILDefiance Trillion Dollar Club Index ETFN/A19.8219.82XERSXeris BiopharmaN/A1.951.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%IFRXInflaRx42.39%IMMPPrima BioMed2.32%TRILDefiance Trillion Dollar Club Index ETF87.15%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.70%IFRXInflaRx16.30%IMMPPrima BioMed3.07%TRILDefiance Trillion Dollar Club Index ETF9.10%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical305.24 million4.89 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableIMMPPrima BioMed2,021147.19 million142.67 millionOptionableTRILDefiance Trillion Dollar Club Index ETF33105.00 million95.44 millionNo DataXERSXeris Biopharma290161.48 million151.03 millionOptionableCLSD, IFRX, XERS, IMMP, and TRIL HeadlinesRecent News About These CompaniesXeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?October 16 at 10:11 AM | zacks.comXeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Time to Buy?October 15 at 2:16 PM | marketbeat.comXeris Biopharma (NASDAQ:XERS) Upgraded to Strong-Buy at Zacks ResearchOctober 15 at 7:45 AM | marketbeat.comBeat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in FocusOctober 13, 2025 | finance.yahoo.comBrokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Price Target at $7.08October 9, 2025 | americanbankingnews.comWeiss Ratings Reiterates Sell (D-) Rating for Xeris Biopharma (NASDAQ:XERS)October 8, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Price Down 4% - Here's What HappenedOctober 8, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsOctober 6, 2025 | marketbeat.comXeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | businesswire.comXeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy?October 3, 2025 | zacks.comXeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?October 3, 2025 | zacks.comXeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - Time to Buy?October 2, 2025 | marketbeat.comStrs Ohio Buys New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 24, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Price Down 7.2% - Should You Sell?September 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Should You Buy?September 19, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Director Sells $119,660.00 in StockSeptember 13, 2025 | insidertrades.comWhat Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comXeris In Recorlev-Fuelled Growth: Why I Choose To BuySeptember 5, 2025 | seekingalpha.comJeffrey Sherman Sells 42,232 Shares of Xeris Biopharma (NASDAQ:XERS) StockAugust 30, 2025 | insidertrades.comXeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 RevenueAugust 29, 2025 | uk.finance.yahoo.comXeris Announces Orange Book Listing of U.S. Patent for Recorlev®August 25, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLSD, IFRX, XERS, IMMP, and TRIL Company DescriptionsClearside Biomedical NASDAQ:CLSD$3.78 +0.08 (+2.16%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.InflaRx NASDAQ:IFRX$1.18 -0.06 (-4.44%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Prima BioMed NASDAQ:IMMP$2.06 -0.04 (-1.71%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Defiance Trillion Dollar Club Index ETF NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Xeris Biopharma NASDAQ:XERS$9.26 +0.12 (+1.26%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Intel's Turnaround Hits Hyperspeed With A New 52-Week High Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Energy Crunch Ahead: 3 Natural Gas Stocks Set to Gain Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
